Product choice and haemophilia treatment in the Netherlands.
In the Netherlands, there is a free choice of product for the treatment of haemophilia. Which product is chosen depends on the following considerations: medical, psychological, availability of clotting products, economics and government guidelines. Since the introduction of recombinant product in 1995, the percentage of Dutch patients treated with it has increased from 8% in 1995 to 20% in 1998. In 1999, an average of 48% of patients visiting the Van Creveldkliniek were treated with recombinant product. Children are more often treated with recombinant product than adults; 93% of children between 0 and 5 years, 53% of children between 6 and 20 years and 40% of adults are treated with recombinant product.
Mauser-Bunschoten
E P
EP
Van Creveldkliniek, University Medical Center Utrecht, The Netherlands. e.mauserbunschoten@digd.azu.nl
Roosendaal
G
G
van den Berg
H M
HM
D000293:Adolescent; D000328:Adult; D001779:Blood Coagulation Factors / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003657:Decision Making; D006467:Hemophilia A / Q000188:drug therapy* / Q000453:epidemiology*; D006801:Humans; D007223:Infant; D009426:Netherlands / Q000453:epidemiology; D011994:Recombinant Proteins / Q000627:therapeutic use
D001779:Blood Coagulation Factors; D011994:Recombinant Proteins